Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer. New research findings — published in the Nature family journal Signal Transduction and Targeted Therapy — suggest that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor that targets the SRC gene to efficiently trigger cell death in AML cells.

Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has emerged as a heterogenous disease tightly linked to metabolic dysfunction and has been redefined under the umbrella term ‘steatotic liver disease’ (SLD). However, CRC risk variations across different SLD subgroups remain unknown. Now, researchers from Japan have discovered that the risk of CRC varies significantly among SLD subgroups, with patients with alcoholic liver disease being at higher risk.